Terms: = Pancreatic cancer AND SETD2, ENSG00000181555, 29072
12 results:
1. setd2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy.
Zheng X; Lin J; Xiong J; Guan Y; Lan B; Li Y; Gao X; Fei Z; Chen L; Chen L; Chen L; Chen G; Guo Z; Yi X; Cao W; Ai X; Zhou C; Li X; Zhao J; Yan X; Yu Q; Si L; Chen Y; Chen C
BMC Cancer; 2023 Jul; 23(1):686. PubMed ID: 37479966
[TBL] [Abstract] [Full Text] [Related]
2. Integrated Genomic and Clinicopathologic Approach Distinguishes pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM
Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102
[TBL] [Abstract] [Full Text] [Related]
3. Tumor Cell-Intrinsic setd2 Deficiency Reprograms Neutrophils to Foster Immune Escape in pancreatic Tumorigenesis.
Niu N; Shen X; Zhang L; Chen Y; Lu P; Yang W; Liu M; Shi J; Xu D; Tang Y; Yang X; Weng Y; Zhao X; Wu LM; Sun Y; Xue J
Adv Sci (Weinh); 2023 Jan; 10(2):e2202937. PubMed ID: 36453584
[TBL] [Abstract] [Full Text] [Related]
4. Glycolysis addiction compensating for a defective pentose phosphate pathway confers gemcitabine sensitivity in setd2-deficient pancreatic cancer.
Shen X; Chen Y; Liu M; Shi J; Tang Y; Yang X; Xu D; Yao H; Lu P; Sun Y; Xue J; Niu N
Biochem Biophys Res Commun; 2022 Jul; 615():9-16. PubMed ID: 35679751
[TBL] [Abstract] [Full Text] [Related]
5. Molecular Characterization of KRAS Wild-type Tumors in Patients with pancreatic Adenocarcinoma.
Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
[TBL] [Abstract] [Full Text] [Related]
6. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
Liu W; Ren D; Xiong W; Jin X; Zhu L
J Exp Clin Cancer Res; 2022 Jan; 41(1):38. PubMed ID: 35081978
[TBL] [Abstract] [Full Text] [Related]
7. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
[TBL] [Abstract] [Full Text] [Related]
8. Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.
Grande E; Rodriguez-Antona C; López C; Alonso-Gordoa T; Benavent M; Capdevila J; Teulé A; Custodio A; Sevilla I; Hernando J; Gajate P; Molina-Cerrillo J; Díez JJ; Santos M; Lanillos J; García-Carbonero R
Oncologist; 2021 Nov; 26(11):941-949. PubMed ID: 34190375
[TBL] [Abstract] [Full Text] [Related]
9. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract] [Full Text] [Related]
10. Expression and prognostic value of NSD1 and setd2 in pancreatic ductal adenocarcinoma and its precursor lesions.
Ettel M; Zhao L; Schechter S; Shi J
Pathology; 2019 Jun; 51(4):392-398. PubMed ID: 31060750
[TBL] [Abstract] [Full Text] [Related]
11. Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.
Roy S; LaFramboise WA; Liu TC; Cao D; Luvison A; Miller C; Lyons MA; O'Sullivan RJ; Zureikat AH; Hogg ME; Tsung A; Lee KK; Bahary N; Brand RE; Chennat JS; Fasanella KE; McGrath K; Nikiforova MN; Papachristou GI; Slivka A; Zeh HJ; Singhi AD
Gastroenterology; 2018 Jun; 154(8):2060-2063.e8. PubMed ID: 29486199
[TBL] [Abstract] [Full Text] [Related]
12. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.
Varela I; Tarpey P; Raine K; Huang D; Ong CK; Stephens P; Davies H; Jones D; Lin ML; Teague J; Bignell G; Butler A; Cho J; Dalgliesh GL; Galappaththige D; Greenman C; Hardy C; Jia M; Latimer C; Lau KW; Marshall J; McLaren S; Menzies A; Mudie L; Stebbings L; Largaespada DA; Wessels LF; Richard S; Kahnoski RJ; Anema J; Tuveson DA; Perez-Mancera PA; Mustonen V; Fischer A; Adams DJ; Rust A; Chan-on W; Subimerb C; Dykema K; Furge K; Campbell PJ; Teh BT; Stratton MR; Futreal PA
Nature; 2011 Jan; 469(7331):539-42. PubMed ID: 21248752
[TBL] [Abstract] [Full Text] [Related]